722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc.

Key Points

• Hennion & Walsh Asset Management acquired 722,928 Allogene Therapeutics shares worth approximately $1.5 million, representing a 0.21% stake. Institutional investors collectively own 83.63% of the company.
• Allogene’s cema-cel program received FDA RMAT and Fast Track designations, while the company plans to expand its ALPHA3 trial to about 100 sites by year-end.
• The company reported a second-quarter loss of $0.13 per share, beating expectations for a $0.17 loss, and revenue of $4.64 million. Despite a consensus “Moderate Buy” rating and $8.52 price target, Allogene remains unprofitable with no approved commercial product.

Hennion & Walsh Asset Management Inc. bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 722,928 shares of the company's stock, valued at approximately $1,504,000. Hennion & Walsh Asset Management Inc. owned 0.21% of Allogene Therapeutics at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ALLO. Kestra Private Wealth Services LLC purchased a new stake in shares of Allogene Therapeutics in the first quarter worth $27,000. Russell Investments Group Ltd. lifted its stake in shares of Allogene Therapeutics by 11,159.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company's stock valued at $27,000 after buying an additional 21,650 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Allogene Therapeutics by 5,267.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company's stock worth $30,000 after buying an additional 23,599 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in Allogene Therapeutics in the 3rd quarter worth $30,000. Finally, Bull Harbor Capital LLC purchased a new stake in Allogene Therapeutics in the 1st quarter worth $31,000. Hedge funds and other institutional investors own 83.63% of the company's stock.

Key Headlines Impacting Allogene Therapeutics

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cema-cel, potentially enabling more frequent regulatory interaction and an expedited review path. Allogene also plans to expand its ALPHA3 trial to approximately 100 sites by year-end, signaling an effort to accelerate enrollment and development. Allogene outlines plan for approximately 100 ALPHA3 sites and FDA grants RMAT and Fast Track
• Positive Sentiment: Allogene reported a second-quarter loss of $0.13 per share, better than the analyst consensus loss of $0.17, while revenue of $4.64 million exceeded expectations of essentially no revenue. The earnings beat may provide modest support for the shares, despite the company remaining unprofitable. Allogene second-quarter 2026 financial results and business update
• Neutral Sentiment: Management’s earnings call focused on advancing cema-cel and expanding the ALPHA3 study. These updates improve the program’s visibility, but the investment case remains dependent on clinical-trial execution, future data and regulatory decisions. Allogene Q2 2026 earnings call transcript
• Negative Sentiment: Allogene continues to report net losses and has no approved commercial product, leaving the company exposed to financing needs and the possibility of disappointing trial results. The FDA designations are not approvals and do not guarantee cema-cel’s success.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. upgraded Allogene Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Thursday, April 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Allogene Therapeutics in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.52.

Allogene Therapeutics Trading Down 2.4%

Shares of Allogene Therapeutics stock opened at $2.07 on Thursday. The stock has a 50 day moving average of $1.95 and a 200 day moving average of $2.12. Allogene Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $4.46. The firm has a market cap of $714.46 million, a PE ratio of -2.69 and a beta of 0.48.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.04. The firm had revenue of $4.64 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities research analysts forecast that Allogene Therapeutics, Inc. will post -0.7 earnings per share for the current fiscal year.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source